Demeetra Agbio, a Rapha portfolio company was recently featured in an article in the leading industry publication, CRISPR News MEDICINE. Demeetra AgBio, headquartered in Kentucky, is pioneering a unique genome-editing technology called Cas-CLOVER. Applications include plant-based drug development, enhanced bioprocessing for human and animal health, and engineering of crops and agricultural animals for improved traits. The author, Karen O’Hanlon Cohrt, spoke with Demeetra’s CEO Jack Crawford to hear more about Cas-CLOVER and its potential within human health and medicine.